DSM-V Revisions Could Open - Or Close - Opportunities For Drug Industry

Drug firms with a major stake in neurologic and psychiatric drug development are closely monitoring the psychiatric profession as it goes through its once-a-generation revamp of the Diagnostic and Statistical Manual of Mental Disorders